JP7827630B2 - 前立腺がんを診断するための新規な方法と化合物 - Google Patents

前立腺がんを診断するための新規な方法と化合物

Info

Publication number
JP7827630B2
JP7827630B2 JP2022552853A JP2022552853A JP7827630B2 JP 7827630 B2 JP7827630 B2 JP 7827630B2 JP 2022552853 A JP2022552853 A JP 2022552853A JP 2022552853 A JP2022552853 A JP 2022552853A JP 7827630 B2 JP7827630 B2 JP 7827630B2
Authority
JP
Japan
Prior art keywords
seq
cdr
prostasomes
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022552853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516705A5 (enExample
JP2023516705A (ja
Inventor
バルデンストレーム アンデシュ
ラーション アンデシュ
Original Assignee
プロスメディック スウェーデン アクティエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロスメディック スウェーデン アクティエボラーグ filed Critical プロスメディック スウェーデン アクティエボラーグ
Publication of JP2023516705A publication Critical patent/JP2023516705A/ja
Publication of JP2023516705A5 publication Critical patent/JP2023516705A5/ja
Application granted granted Critical
Publication of JP7827630B2 publication Critical patent/JP7827630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022552853A 2020-03-03 2021-03-01 前立腺がんを診断するための新規な方法と化合物 Active JP7827630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20160712.4 2020-03-03
EP20160712.4A EP3875482A1 (en) 2020-03-03 2020-03-03 New method and compound for prostate cancer diagnosis
PCT/EP2021/055061 WO2021175788A1 (en) 2020-03-03 2021-03-01 New method and compound for prostate cancer diagnosis

Publications (3)

Publication Number Publication Date
JP2023516705A JP2023516705A (ja) 2023-04-20
JP2023516705A5 JP2023516705A5 (enExample) 2024-02-26
JP7827630B2 true JP7827630B2 (ja) 2026-03-10

Family

ID=69770502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552853A Active JP7827630B2 (ja) 2020-03-03 2021-03-01 前立腺がんを診断するための新規な方法と化合物

Country Status (7)

Country Link
US (1) US20230093265A1 (enExample)
EP (2) EP3875482A1 (enExample)
JP (1) JP7827630B2 (enExample)
CN (1) CN115210256A (enExample)
AU (1) AU2021232524A1 (enExample)
CA (1) CA3168158A1 (enExample)
WO (1) WO2021175788A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI131968B1 (en) * 2023-10-16 2026-03-17 Teknologian Tutkimuskeskus Vtt Oy ANTIBODY BINDINGS AS CANCER BIOMARKERS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525761A (ja) 2010-04-16 2013-06-20 プロスタソム ハンデルスボラグ 癌診断のための方法およびキット
US20130196316A1 (en) 2012-01-26 2013-08-01 Masood Kamali Moghaddam Detection of single and multimodal analytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012553A1 (en) * 1997-09-08 1999-03-18 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525761A (ja) 2010-04-16 2013-06-20 プロスタソム ハンデルスボラグ 癌診断のための方法およびキット
US20130196316A1 (en) 2012-01-26 2013-08-01 Masood Kamali Moghaddam Detection of single and multimodal analytes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Entomol. Zool. Stud.，2018年，Vol.6，pp.2464-2471
Proc. Natl. Acad. Sci.，2011年，Vol.108，pp.8809-8814

Also Published As

Publication number Publication date
CN115210256A (zh) 2022-10-18
CA3168158A1 (en) 2021-09-10
EP4114853A1 (en) 2023-01-11
US20230093265A1 (en) 2023-03-23
EP3875482A1 (en) 2021-09-08
AU2021232524A1 (en) 2022-09-29
WO2021175788A1 (en) 2021-09-10
JP2023516705A (ja) 2023-04-20

Similar Documents

Publication Publication Date Title
JP6180931B2 (ja) 癌の診断および／または予後のための新規な抗体
CN110651190A (zh) 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
EP3094976B1 (en) Cell surface prostate cancer antigen for diagnosis
JP7156622B2 (ja) 前立腺癌検出のための組成物と方法
CN111770761B (zh) H1.0k180me2抗体、其制造方法和用途
AU2017204683B2 (en) Compositions and methods for assessing the risk of cancer occurrence
US11009507B2 (en) Methods and diagnostics for cancer detection and treatment monitoring
JP2023516705A (ja) 前立腺がんを診断するための新規な方法と化合物
US20210148911A1 (en) Methods and Diagnostics for Cancer Detection and Treatment Monitoring
FI131968B1 (en) ANTIBODY BINDINGS AS CANCER BIOMARKERS
CA3009768C (en) Compositions and methods for assessing the risk of cancer occurrence
HK1262633B (en) Compositions and methods for assessing the risk of cancer occurrence
EA043033B1 (ru) Способ оценки риска возникновения рака, соответствующие набор, блок хранения данных и обрабатывающая система
EA041328B1 (ru) Композиции и способы для диагностики рака предстательной железы
HK1248730B (en) Igf-1r antibody and its use for the diagnosis of cancer
HK1225791B (en) Cell surface prostate cancer antigen for diagnosis
HK1243434B (en) Igf-1r antibody and its use for the diagnosis of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260226

R150 Certificate of patent or registration of utility model

Ref document number: 7827630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150